Gestoden; Gestodenum [INN-Latin]; Gestodeno [INN-Spanish]; SH B 331; UNII-1664P6E6MI; 1664P6E6MI; SH-B-331; Gestinol; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17a)-; DSSTox_CID_26478; DSSTox_RID_81649; DSSTox_GSID_46478; Gestodenum; Gestodeno; 13beta-Ethyl-17beta-hydroxy-18,19-dinorpregna-4,15-dien-20-yn-3-one; Gestodene [USAN:INN:BAN]; CCRIS 9189; HSDB 3594; EINECS 262-145-8; BRN 4237181; NCGC00164611-01; Gestodene (USAN/INN); 17-alpha-Ethinyl-13-ethyl-17-beta-hydroxy-4,15-gonadien-3-one; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregna-4,15-dien-20-yn-3-one; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-; SCHEMBL37271; CHEMBL1213583; DTXSID6046478; Gestodene, >=98% (HPLC); GTPL11246; SHB-331; SHT-546; BCP22665; HY-B0110; Tox21_112232; AC-474; BDBM50247973; MFCD00867858; s1376; SH-546; AKOS024462671; Femodene (ethinylestradiol, gestodene); Tox21_112232_1; ZINC238809420; CCG-267584; CS-1862; DB06730; Millinette (ethinylestradiol, gestodene); Pregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-18,19-dinor-, (17alpha)-; NCGC00263565-01; AC-20038; AS-13029; SC-27288; G0404; D04316; AB01274782-01; AB01274782_02; 282G873; A832668; Q408289; Q-101426; BRD-K97197005-001-03-2; Gestodene, European Pharmacopoeia (EP) Reference Standard; 17alpha -Ethynyl-17beta-hydroxy-18-methyl-4,15-estradien-3-one; 17alpha-ethynyl-17beta-hydroxy-18-methyl-4,15-estradien-3-one; 17alpha-ethynyl-17beta-hydroxy-18-methyl-estra-4,15-dien-3-one